尼莫拉唑增强放化疗在头颈癌中的转录组与表观遗传学全景
本研究利用五种头颈鳞癌异种移植瘤模型,在10次分次放化疗联合或不联合尼莫拉唑后行RNA测序和DNA甲基化检测,发现尼莫拉唑应答与非应答模型间缺氧基因特征无差异,但非应答模型代谢通路上调,其中15个差异表达基因可将DKTK-ROG队列患者分为不同预后组。
要点
- 尼莫拉唑应答与非应答肿瘤模型的缺氧基因特征无差异。
- 非应答模型表现为代谢通路上调,包括视黄醇代谢和异源物质代谢过程通路。
- 15个差异表达基因可将接受原发放化疗的HNSCC患者分为低危和高危组,两组结局不同。
核心结论
- 尼莫拉唑非应答模型的特征是视黄醇代谢和异源物质代谢过程通路相关基因上调,可能有助于识别硝基咪唑类化合物的耐药机制并潜在扩展HNSCC治疗选择。
研究设计与样本
- 使用未处理及经10次分次放化疗联合或不联合尼莫拉唑处理后的HNSCC异种移植瘤行批量RNA测序和DNA甲基化实验,肿瘤模型包括FaDu、SAS、Cal33、SAT和UT-SCC-45。
- 利用DKTK-ROG中接受原发放化疗的HNSCC患者的临床和基因表达数据评估候选基因的预后影响。
主要发现
- 尼莫拉唑应答与非应答肿瘤模型的缺氧基因特征无差异。
- 非应答模型显示代谢通路上调。
- 15个差异表达基因将HNSCC患者分为低危和高危组,两组结局不同。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypoxia remains a challenge for the therapeutic management of head and neck squamous cell carcinoma (HNSCC). The combination of radiotherapy with nimorazole has shown treatment benefit in HNSCC, but the precise underlying molecular mechanisms remain unclear. PURPOSE: To assess and to characterize the transcriptomic/epigenetic landscape of HNSCC tumor models showing differential therapeutic response to fractionated radiochemotherapy (RCTx) combined with nimorazole. MATERIALS/METHODS: Bulk RNA-sequencing and DNA methylation experiments were conducted using untreated and treated HNSCC xenografts after 10 fractions of RCTx with and without nimorazole. These tumor models (FaDu, SAS, Cal33, SAT and UT-SCC-45) previously showed a heterogeneous response to RCTx with nimorazole. The prognostic impact of candidate genes was assessed using clinical and gene expression data from HNSCC patients treated with primary RCTx within the DKTK-ROG. RESULTS: Nimorazole responder and non-responder tumor models showed no differences in hypoxia gene signatures However, non-responder models showed upregulation of metabolic pathways. From that, a subset of 15 differentially expressed genes stratified HNSCC patients into low and high-risk groups with distinct outcome. CONCLUSION: In the present study, we found that nimorazole non-responder models were characterized by upregulation of genes involved in Retinol metabolism and xenobiotic metabolic process pathways, which might contribute to identify mechanisms of resistance to nitroimidazole compounds and potentially expand the repertoire of therapeutic options to treat HNSCC.
引用
- Besso MJ, Bitto V, Koi L, et al. Transcriptomic and epigenetic landscape of nimorazole-enhanced radiochemotherapy in head and neck cancer. Radiother Oncol. 2024. PMID: 38823583. doi:10.1016/j.radonc.2024.110348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。